Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Dose Escalation and Expansion Study of VTRU200 in Adult and Pediatric Participants With Relapsed/Refractory AML, HR-MDS, DLBCL Post-CART Failure and Advanced Solid Tumors

NCT07749976 is registered in ClinicalTrials.gov with Vitruviae as lead sponsor.

NCT NCT07749976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07749976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Dose Escalation and Expansion Study of VTRU200 in Adult and Pediatric Participants With Relapsed/Refractory AML, HR-MDS, DLBCL Post-CART Failure and Advanced Solid Tumors
Lead sponsor
Vitruviae
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
January 31, 2029
Enrollment
108 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, diffuse large b cell lymphoma (dlbcl), high risk myelodysplastic syndrome, pediatric acute myeloid leukemia, solid tumor malignancies